Trials / Completed
CompletedNCT02522767
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate the efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC. Subject will receive 4 g extended release granules (sachet) once daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesalamine | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-02-06
- Completion
- 2018-04-03
- First posted
- 2015-08-13
- Last updated
- 2021-03-15
- Results posted
- 2021-03-15
Locations
93 sites across 11 countries: United States, Bulgaria, Canada, Hungary, Latvia, Mexico, Poland, Russia, Serbia, Switzerland, Ukraine
Source: ClinicalTrials.gov record NCT02522767. Inclusion in this directory is not an endorsement.